Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates
Following court injunctions, some states and cities regained funding, while others experienced continued cancellations that affected immunization clinics, workforce capacity, and infectious-disease surveillance.